key: cord-0253843-zrcbjxu1
authors: Reynolds, M. W.; Xie, Y.; Knuth, K. B.; Mack, C. D.; Brinkley, E.; Toovey, S.; Dreyer, N. A.
title: COVID-19 vaccination breakthrough infections in a real-world setting: Using community reporters to evaluate vaccine effectiveness
date: 2022-01-11
journal: nan
DOI: 10.1101/2022.01.11.22268736
sha: 7a8db74cbc41c0775899ad14255c933366360412
doc_id: 253843
cord_uid: zrcbjxu1

Background COVID-19 has highlighted the need for new methods of pharmacovigilance. Here we use community volunteers to obtain systematic information on vaccine effectiveness and the nature and severity of breakthrough infections. Methods Between December 15, 2020 to September 16, 2021, 10,412 unpaid community-based participants reported the following information to an on-line registry: COVID-19 test results, vaccination (Pfizer, Moderna, or Johnson & Johnson), COVID-19 symptoms and perceived severity using a 4-point scale. COVID-19 infections were described for those who were 1) fully vaccinated, 2) partially vaccinated (received first of two dose vaccines or were <14 days post-final dose), or 3) unvaccinated. Results Of 8,554 who were vaccinated, COVID-19 infections were reported by 74 (1.0%) of those who were fully vaccinated and 198 (2.3%) of those who were partially vaccinated. Among the 74 participants who reported a breakthrough infection after full vaccination, the median time to reported positive test result was 104.5 days (Interquartile range: 77-135 days), with no difference among vaccine manufactures. One quarter (25.7%) of breakthrough infections in the fully vaccinated cases were asymptomatic. More than 97% of fully vaccinated participants reported no moderate/severe symptoms compared to 89.3% of the unvaccinated cases; and only 1.4% of fully vaccinated participants reported experiencing at least 3 moderate to severe symptoms compared to 7.8% in the unvaccinated. Conclusion Person-generated health data, also referred to as patient-reported outcomes, is a useful resource for quantifying breakthrough infections and their severity, showing here that fully vaccinated participants report no or very mild COVID-19 symptoms.

The three COVID-19 vaccines authorized by the United States Food and Drug Administration (FDA) as of this writing have been found to be safe and highly efficacious in preventing symptomatic, laboratory-confirmed COVID-19 infections in randomized controlled trials. [1] [2] [3] As is not uncommon with even the most effective vaccines, the currently authorized COVID-19 vaccines confer infection-permissive or ´non-sterilizing' immunity, i.e. while they may not always prevent infection, they will prevent or protect against illness, and particularly severe illness. 4 Infection in the vaccinated is referred to as a 'breakthrough' infection; such cases are defined by the US Centers for Disease Control and Prevention (CDC) as those which have detectable SARS-CoV-2 RNA or antigen on a respiratory specimen collected ≥ 14 days after completion of a vaccine regimen. 1 While cases of COVID-19 might still be expected to occur after vaccination, an excess of breakthrough infections could suggest a possible lack of vaccine effectiveness, consistent with the FDA definition of an adverse event as including "failure to produce the expected pharmacologic action". 5 One consideration of vaccine effectiveness would be the ability to reduce or prevent severe symptoms in those infected with SARS-CoV-2.

Hence, while it is important to identify breakthrough cases, it is equally important to characterize the severity of the associated symptoms.

Understanding the safety of these new vaccines in the general population is of particular concern, both in terms of stemming the SARS-CoV-2 pandemic and of assuaging the vaccine hesitancy occasioned by the accelerated development of the currently available COVID-19

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint vaccines. 6, 7 Lack of drug effectiveness has been proven to be the most commonly reported adverse event (AE) in the US FDA Adverse Event Reporting System (FAERS), 6 driven primarily by spontaneous adverse event reporting from consumers. From the pharmacovigilance perspective, assessing lack of drug efficacy can be challenging, with difficulties such as the definition of a simple or clear metric for an endpoint, and in this case, a lack of national systematic surveillance to detect infection. Such assessment is however especially relevant and important for these new COVID-19 vaccines which underwent accelerated evaluation and subsequently were rapidly deployed. Furthermore, the emergence of viral mutations conferring possible vaccine escape, including some known 'variants of concern', makes prompt detection of "lack of effectiveness" signals a public health imperative. 8 While some serious safety concerns remain for these vaccines, e.g. anaphylaxis 9,10 and Guillain-Barre Syndrome, 11 lack of vaccine effectiveness is of particular importance given the potential risk of severe COVID-19 disease and mortality. Lack of ability to effectively prevent, or to minimize, symptoms of infection, would imperil the success of current pandemic control efforts. Person-generated real-world data, sometimes called patient-reported health data or patient reported outcomes, should help to better understand and characterize breakthrough infections.

The objective of this work was to describe the pattern and characteristics of infections after vaccinations in recipients who received any of the three COVID-19 vaccines currently authorized for use in the U.S. (BioNTech (Pfizer), Moderna, Inc. (Moderna), and Janssen Pharmaceuticals (Johnson & Johnson (J&J)) or were never vaccinated. We describe the number . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint of infections reported and patient-reported COVID-19 symptom information, stratified by vaccination status (fully vaccinated, partially vaccinated, and unvaccinated).

Additionally, we illustrate how data generated by health care recipients (in this case patients with confirmed COVID-19 infections) can be used for pharmacovigilance.

We leveraged data from a web-based registry, the COVID- 19 tests, COVID-19 vaccination, and use of prescription and non-prescription medications and dietary supplements. Those who report having been vaccinated are also asked to provide the date of vaccination and side effects for first and second doses, as appropriate, manufacturer, and lot number, if known; participants are instructed to refer to their vaccination card to . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint enhance data accuracy. Participants are asked to complete surveys once a week for the first month, and then twice a month for months two through twelve.

Surveys were submitted by 11,927 participants between December 15, 2020 and September 16, 2021. We excluded 101 reports of unauthorized vaccines, receipt of doses from more than one manufacturer, inconsistent dates, or vaccine dates earlier than June 2020. We also excluded participants who were unvaccinated and did not report a positive COVID-19 test . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint 

There were 10,412 participants in our sample, including 8,554 who reported receiving at least one dose of an FDA-authorized vaccine and 1,858 who were never vaccinated but reported a positive COVID-19 test. The average age among the 8,554 vaccinated study participants was 47.9 years (range: 18-91 years); the majority were female (83.4%), with some college or higher education (90.8%), White (89.9%), non-smokers (90.4%), and received vaccination for influenza . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint (73.7%) ( Table 1) . Among the 8,554 fully or partially vaccinated participants, 1,160 (13.6%) reported having an infection before any COVID-19 vaccination.

The counts of participants who reported a positive COVID-19 test before receiving their first vaccination (n=1,160) and those who were never vaccinated and reported a positive COVID-19 test (n=1,858) are shown in Table 2 There were small differences in age across the three vaccination status groups, with 24.3% of people aged > 60 years in the fully vaccinated group and 15.7% and 12.2% in partially . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint vaccinated and unvaccinated, respectively. Partially vaccinated and unvaccinated groups also had lower proportion of males (13.1% and 13.1% compared with 17.6% among fully vaccinated) and above college education (31.8% and 20.3%, compared with 40.5% among fully vaccinated).

Other demographics and medical characteristics appeared to be similar across the three subgroups. Approximately one quarter (25.7%) of fully vaccinated breakthrough cases reported no symptoms compared with 13.6% and 16.4% among partially vaccinated and unvaccinated cases, respectively ( Figure 3 ). Fully vaccinated breakthrough cases were also more likely to report only mild symptoms and not report moderate or severe symptoms (97.3%) compared with partially vaccinated or unvaccinated cases (92.4% and 89.3%, respectively) ( Table 4 and Figure 4 ).

Systematic collection of person-generated health data as illustrated by the CARE registry demonstrates the value of coupling symptom information with COVID-19 test data to provide . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. meaningful and timely information about vaccine effectiveness. This study provides quantitative estimates of whether and how intensely cases of COVID-19 occur in people who are fully vaccinated, a question of importance given the continuing emergence of variants of concern. 15 By far the majority of the infections reported in this study occurred before day 14 after recipient's final dose, noting that a relatively limited follow-up time precludes investigation of wanning immunity. Our findings confirm earlier reports. 1, 16 This study provides confirmatory evidence that vaccination, although 'non-sterilizing' or 'infection-permissive', affords significant protection against severe symptoms of COVID-19 disease, and suggests that it also confers protection against infection overall. In this cohort, 0.9% of all participants reported infections after full vaccination, which is consistent with the low rates reported elsewhere. 17 Strikingly, approximately 25% of infections reported by fully vaccinated individuals were asymptomatic. Moreover, fully vaccinated individuals who experienced breakthrough infections reported significantly fewer symptoms than partially vaccinated or unvaccinated cases, with only a small fraction of fully vaccinated cases reporting moderate or severe symptoms and about one quarter experienced no symptoms at all. Thus, our findings are consistent with many studies reporting that only a small proportion of breakthrough cases are severe, and that a significant proportion of breakthrough infections are mild or asymptomatic. 16, [18] [19] [20] [21] In this study, there were a few differences between the participants who reported COVID-19 infection after full vaccination and those who reported infection while partially vaccinated. The fully vaccinated group had a slightly higher proportion of infection in males, individuals aged 60 years or above and those with at least a college education. Reasons for the differences are not . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint clear; potential explanations include that these participants (older and more educated) may have been vaccinated earlier, and thus have had a longer time after being fully vaccinated; such individuals would have had a longer 'at risk' time and/or potentially waning immunity. Older age (>60 years) might also reflect a degree of immunosenescence and a less robust response to vaccination. 22 It should be noted that several factors that might be expected to be associated with an increased risk of infection such as hypertension, diabetes, and obesity, were not Similarly, COVID-19 test results are also likely to be more complete than in some existing realworld databases, since participants were systematically queried to see if they were tested at every bi-weekly follow-up. Furthermore, these data were collected and able to be analyzed in near real-time, thus providing an opportunity to conduct pharmacovigilance activities rapidly and allowing for immediate opportunity to intervene if and when merited.

Nonetheless it is important to keep in mind that, like other online registries that survey volunteers without intervention or collaboration from medical care providers, the CARE registry . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint relies on participants to contribute information completely, faithfully and accurately. Missing data, especially outcomes of interest, are possible and these data were not validated with respect to documenting the COVID-19 tests or obtaining a clinical assessment of the personreported symptoms. Nevertheless, the validity of reports from lay people on medication use has been demonstrated, 1 and as such, reporting quality is likely to apply at least as well to vaccine reporting. Using a direct to patient/person approach for future pharmacovigilance activities could support incorporation of exposure or outcome validation via direct to patient/physician follow-up and/or linkage to patient medical records.

There also may be underreporting of breakthrough cases and potential misclassification of their . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint Furthermore, projects like this tend to attract more females as well as those "worried well," with higher participation among those with autoimmune disorders as well as anxiety, depression and insomnia. More importantly, it is unlikely that there was differential participation by vaccine manufacturers. Therefore comparisons between vaccine manufacturers in the CARE population are not likely to be biased.

The systematic collection of person-generated health data shows that only a small proportion of vaccinated people become infected after vaccination, and they are more likely to be asymptomatic or have fewer and milder symptoms than unvaccinated people. This insight supports the evidence that COVID-19 vaccines are effective in the real world and that while cases of COVID-19 may occur in vaccinated individuals, these are uncommon, and generally mild in nature. The vaccines appear to be effective at preventing severe disease. This efficient direct-to-patient approach can obtain information not readily available in most real world data sources, and can be used effectively to study adverse events including product effectiveness.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. 

Hospitalized 54(1.6) 49(1.6) 4(2) 1(1.4) *Unvaccinated group included participants reporting infection before any vaccination and those reporting infection and never vaccinated . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure 3 . Number of symptoms reported by vaccination status . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22268736 doi: medRxiv preprint

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Nonsterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses

Guideline for Postmarketing Reporting of Adverse Drug Experiences

An Evaluation of "Drug Ineffective

Geneva: Council for International Organizations of Medical Sciences (CIOMS)

Development and rational use of standardised MedDRA queries (SMQs): Retrieving adverse drug reactions with MedDRA

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Guillain-Barre Syndrome Associated with COVID-19 Vaccination

Self-reported symptoms from exposure to Covid-19 provide support to clinical diagnosis, triage and prognosis: An exploratory analysis

Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19

How frequent are acute reactions to COVID-19 vaccination and who is at risk? doi

Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines

SARS-CoV-2 infections after vaccination -what we know so far. Toronto, ON: Queen's Printer for Ontario

COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members

Asymptomatic and Symptomatic SARS-CoV-2

Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

Marin records 21 'breakthrough' infections after COVID-19 vaccines. The Mercury News

Oregon reports small number of COVID cases in vaccinated people

Chapter 3 -Special Considerations for Vaccines and the Elderly

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

We thank Lisa Albert for her work on preliminary analyses, Savitha Pallipuram for leading the Technical team, and Alex Secora for his thoughtful editing contributions.